Date: 21 Nov 2012
Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care Organisation
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Data on the incidence of serious allergic reactions to fluoroquinolone antibacterials are mainly derived from spontaneous reports that cannot be used to accurately estimate incidence.
Methods: This study estimated the drug-specific incidence of serious allergic reactions after fluoroquinolone, cephalosporin and phenoxymethylpenicillin potassium exposure, using claims for healthcare services with confirmation through medical record abstraction within a large health insurer database. Cohorts exposed to each antibacterial of interest (moxifloxacin, levofloxacin, ciprofloxacin, gatifloxacin, cephalosporins and penicillin) were identified, and followed for 14 days for anaphylaxis (9th revision of the International Classification of Diseases [ICD-9] code 995.0), other allergic drug reactions (ICD-9 995.2, 995.3) or cardiopulmonary resuscitation.
Results: The incidence per 10 000 first dispensings of any allergic diagnosis made in the hospital or emergency department was similar for moxifloxacin (4.3; 95% CI 3.5, 5.3), penicillin (4.7; 95% CI 3.8, 5.7) and ciprofloxacin (5.4; 95% CI 4.4, 6.5). The incidence for moxifloxacin was lower than that for levofloxacin (8.7; 95% CI 7.4, 10.0), gatifloxacin (6.7; 95% CI 5.6, 7.9) and the cephalosporins (7.5; 95% CI 6.3, 8.8). The incidence of anaphylaxis/anaphylactoid reactions after first dispensings was similar for the fluoroquinolones: 0.1 (95% CI 0.0, 0.3) for ciprofloxacin, 0.3 (95% CI 0.1, 0.5) for moxifloxacin, 0.3 (95% CI 0.1, 0.6) for gatifloxacin and 0.5 (95% CI 0.3, 0.9) for levofloxacin; and comparable with that of the cephalosporins (0.2; 95% CI 0.0, 0.4) and penicillin (0.1; 95% CI 0.0, 0.3).
Conclusions: Anaphylactic reactions were rare and their incidence did not differ substantially among the drug groups studied. By determining the occurrence of reactions following defined exposures, these results provide a context for the interpretation of spontaneous reports of allergic reactions.
Campi P, Pichler WJ. Quinolone hypersensitivity. Curr Opinion Allergy Immunol 2003; 3: 275–81CrossRef
Lieberman PL. Chapter 83: Anaphylaxis and anaphylactoid reactions. In: Adkinson NF, Yunginger JW, Busse WW, et al., editors. Middleton’s allergy: principles and practice. 6th ed. St Louis (MO): Mosby, Inc., 2003
Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill, 2005
Muelleman RL, Tran TP. Chapter 113: Allergy, hypersensitivity, and anaphylaxis. In: Rosen’s emergency medicine: concepts and clinical practice. 5th ed. St Louis (MO): Mosby, Inc., 2002
Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Pt 2): 253–72SCrossRef
Assouad M, Willcourt RJ, Goodman PH. Anaphylactoid reactions to ciprofloxacin. Ann Internal Med 1995; 122: 396–7
Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989; 111: 1041–3PubMed
Alemán AM, Quirce S, Cuesta J, et al. Anaphylactoid reaction caused by moxifloxacin. J Invest Allergol Clin Immunol 2002; 12: 67–8
Rothman KJ. Epidemiology an introduction. New York: Oxford University Press, 2000: 134
Gilman AG, Goodman LS, Rall TW, Murad F. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company, 1985: 1135
- Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care Organisation
Volume 30, Issue 8 , pp 705-713
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. i3 Drug Safety, 950 Winter St, Suite 3800, Waltham, Massachusetts, MA 02451, USA
- 2. RTI Health Solutions, Waltham, Massachusetts, USA
- 3. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
- 4. Bayer Healthcare, Bayer Pharmaceuticals Corporation, West Haven, Connecticut, USA
- 5. Bayer Healthcare AG, Leverkusen, Germany
- 6. United Biosource Corporation, Ambler, Pennsylvania, USA